
    
      This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in
      Met exon 14 skipping Advanced Non-small Cell Lung Cancer . We will analysis 100 met exon 14
      skipping advanced non-small cell lung cancer who treated with crizotninb or chemotherapy for
      PFS and OS.
    
  